Dupilumab is a human monoclonal antibody to the interleukin-4 (IL-4) receptor which leads to a decrease in production inflammatory mediators of allergic symptoms and is used in the therapy of atopic dermatitis. Dupilumab therapy has not been associated with serum enzyme elevations or to instances of clinically apparent drug induced liver injury. It is grouped under the following drug class(es): Interleukin Inhibitors and Monoclonal antibodies. Its therapeutic use is listed as anti-asthmatic agents and anti-inflammatories. The directory classifies it as a commercial API with a biotechnology source/manufacturing origin. Other names for this substance include Dupixent and Dupilumabum. Its PubChem SID is 481101603.
Dupilumab
| CAS No | 1190264-60-8 |
|---|
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Dupilumab is a human monoclonal antibody to the interleukin-4 (IL-4) receptor which leads to a decrease in production inflammatory mediators of allergic symptoms and is used in the therapy of atopic dermatitis.
The listed CAS number is 1190264-60-8.
The source lists Dupixent and Dupilumabum.
Its therapeutic use is listed as anti-asthmatic agents and anti-inflammatories.
It is listed under Interleukin Inhibitors and Monoclonal antibodies.
It is listed as a commercial API with a biotechnology origin.